Featured Press Releases

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

Aptar’s Nasal Unidose System will deliver neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis

Aptar’s Nasal Unidose System will deliver neffy® (epinephrine nasal spray), the first FDA-approved needle-free treatment for Type I allergic reactions, including anaphylaxis

  • 15 Aug 2024

AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection...

T3D Therapeutics to present Phase 2 results of T3D-959 for reducing Alzheimer

T3D Therapeutics to present Phase 2 results of T3D-959 for reducing Alzheimer's amyloid plaques

Kenox Pharmaceuticals announces a strategic collaboration with Lactiga to advance immunotherapy targeting mucosal areas

Kenox Pharmaceuticals announces a strategic collaboration with Lactiga to advance immunotherapy targeting mucosal areas

To Redefine Specialty Care, Craft Telemedicine Launches with a Human-Centered Platform

To Redefine Specialty Care, Craft Telemedicine Launches with a Human-Centered Platform

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

BrainStorm Cell Therapeutics appoints Peter J. Pitts to its board.

BrainStorm Cell Therapeutics appoints Peter J. Pitts to its board.

  • rainStorm Cell Therapeutics Inc.
  • 28 May 2026
Nestlé and IdB Holding S.p.A. sign VOWST® licensing deal in Europe

Nestlé and IdB Holding S.p.A. sign VOWST® licensing deal in Europe

  • Nestlé Health Science U.S.
  • 28 May 2026
Ori Biotech and ImmuXell Announce Strategic Partnership and First Patient Dosed

Ori Biotech and ImmuXell Announce Strategic Partnership and First Patient Dosed

  • Ori Biotech
  • 27 May 2026
SK bioscience Signs Technology Transfer Agreement with Colombia’s VECOL to Advance Local Vaccine Manufacturing in Latin America

SK bioscience Signs Technology Transfer Agreement with Colombia’s VECOL to Advance Local Vaccine Manufacturing in Latin America

  • SK bioscience
  • 27 May 2026
Presentations Highlight Results on LEROCHOL® (lerodalcibep-liga) Announced by LIB Therapeutics

Presentations Highlight Results on LEROCHOL® (lerodalcibep-liga) Announced by LIB Therapeutics

  • LIB Therapeutics Inc.
  • 27 May 2026
Lundbeck Receives Marketing Authorization in South Korea for Vyepti® (eptinezumab) for the Preventive Treatment of Migraine

Lundbeck Receives Marketing Authorization in South Korea for Vyepti® (eptinezumab) for the Preventive Treatment of Migraine

  • H. Lundbeck A/S
  • 26 May 2026
The Digital Pharma Advances Conference 2026

Most Popular
May   2026
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.